NCT06384807 - A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Biotech Hunter

Enrollment

280

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions

Solid Tumor

Interventions

DRUG

BHV-1510

BHV-1510 will be administered as an IV infusion on Day 1 every 3 weeks

DRUG

Cemiplimab

cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks

DRUG

BHV-1510

BHV-1510 will be administered as an IV infusion on Day 1 every 2 weeks

DRUG

BHV-1510

BHV-1510 will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks

DRUG

Cemiplimab

cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks

Trial Locations (17)

10021

RECRUITING

Site-117, New York

19107

RECRUITING

Site-108, Philadelphia

20016

RECRUITING

Site-114, Washington D.C.

22031

RECRUITING

Site-102, Fairfax

30912

RECRUITING

Site-110, Augusta

32827

RECRUITING

Site-105, Orlando

33176

RECRUITING

Site-103, Miami

33612

RECRUITING

Site-115, Tampa

37203

RECRUITING

Site-107, Nashville

48201

RECRUITING

Site-109, Detroit

63108

RECRUITING

Site-101, St Louis

73117

RECRUITING

Site-116, Oklahoma City

75231

RECRUITING

Site-104, Dallas

84119

RECRUITING

Site-106, West Valley City

91010

RECRUITING

Site-113, Duarte

92093

RECRUITING

Site-112, La Jolla

94304

RECRUITING

Site-111, Palo Alto